Amphastar Pharmaceuticals Advances Governance and Shareholder Value

Amphastar Pharmaceuticals (AMPH) has shared an update.

Amphastar Pharmaceuticals, Inc.’s stockholders made significant decisions at the 2024 Annual Meeting, including the approval of an amended 2015 Equity Incentive Plan and the election of four Class II directors. Additionally, Ernst & Young LLP was ratified as the independent accounting firm for the upcoming fiscal year, and executive officer compensation received approval in an advisory vote. Further bolstering investor confidence, the company announced a $50 million expansion to its share buyback program, aimed at mitigating equity compensation dilution and enhancing shareholder value.

See more data about AMPH stock on TipRanks’ Stock Analysis page.